The global structural heart imaging market size is calculated at USD 9.44 billion in 2024, grew to USD 9.99 billion in 2025 and is projected to reach around USD 16.76 billion by 2034. The market is expanding at a CAGR of 5.91% between 2024 and 2034. The North America structural heart imaging market size is evaluated at USD 3.40 billion in 2024 and is expected to grow at a CAGR of 5.89% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Structural Heart Imaging Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Structural Heart Imaging Market, by Modality, 2024-2034
8.1.1. Echocardiogram
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Angiogram
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. CT
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. MRI
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Nuclear Imaging
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2034)
9.1. Structural Heart Imaging Market, by Procedure, 2024-2034
9.1.1. Transcatheter Aortic Valve Replacement (TAVR)
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Surgical Aortic Valve Replacement (SAVR)
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Transcatheter Mitral Valve Repair (TMVR)
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Left Atrial Appendage Closure (LAAC)
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Annuloplasty
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Valvuloplasty
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2021-2034)
10.1. Structural Heart Imaging Market, by Application, 2024-2034
10.1.1. Valvular Heart Disease
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Congenital Heart Disease
10.1.2.1. Market Revenue and Forecast (2021-2034)
11.1. Structural Heart Imaging Market, by End-use, 2024-2034
11.1.1. Hospitals And Clinics
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Ambulatory Surgical Centers
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Diagnostic Imaging Centers
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Modality (2021-2034)
12.1.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.1.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.4. Market Revenue and Forecast, by End-use (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Modality (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.5.4. Market Revenue and Forecast, by End-use (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Modality (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.6.4. Market Revenue and Forecast, by End-use (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Modality (2021-2034)
12.2.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.2.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.4. Market Revenue and Forecast, by End-use (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Modality (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.5.4. Market Revenue and Forecast, by End-use (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Modality (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.6.4. Market Revenue and Forecast, by End-use (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Modality (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.7.4. Market Revenue and Forecast, by End-use (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Modality (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.8.4. Market Revenue and Forecast, by End-use (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Modality (2021-2034)
12.3.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.3.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.4. Market Revenue and Forecast, by End-use (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Modality (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.5.4. Market Revenue and Forecast, by End-use (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Modality (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.6.4. Market Revenue and Forecast, by End-use (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Modality (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.7.4. Market Revenue and Forecast, by End-use (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Modality (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.8.4. Market Revenue and Forecast, by End-use (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Modality (2021-2034)
12.4.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.4.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.4. Market Revenue and Forecast, by End-use (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Modality (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.5.4. Market Revenue and Forecast, by End-use (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Modality (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.6.4. Market Revenue and Forecast, by End-use (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Modality (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.7.4. Market Revenue and Forecast, by End-use (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Modality (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.8.4. Market Revenue and Forecast, by End-use (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Modality (2021-2034)
12.5.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.4. Market Revenue and Forecast, by End-use (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Modality (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.5.4. Market Revenue and Forecast, by End-use (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Modality (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Procedure (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.6.4. Market Revenue and Forecast, by End-use (2021-2034)
13.1. GE Healthcare
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Siemens Healthineers AG
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Koninklijke Philips N.V
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Canon Medical System, USA
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Boston Scientific Corporation
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Medtronic
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Edwards Lifesciences Corporation
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Bracco
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. FUJIFILM Holdings Corporations
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Hitachi, Ltd
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample